Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart disease
Biotech
Braveheart pays $65M to challenge BMS for heart disease market
Braveheart has waded into the fight for a heart disease market, paying $65 million upfront for a rival to BMS’ Camzyos and Cytokinetics’ aficamten.
Nick Paul Taylor
Sep 5, 2025 9:05am
Corsera launches with $50M for predictive AI tool, RNAi asset
Sep 2, 2025 6:30am
Sanofi scoops up China rights to Cytokinetics' heart disease med
Dec 20, 2024 11:07am
Lilly's lipoprotein-blocking heart drug posts midstage trial win
Nov 19, 2024 9:55am
Cell lines could lead to new drugs for deadly heart condition
Jun 4, 2024 2:12pm
Arrowhead's cholesterol drug hits the mark again in ph. 2 trial
May 28, 2024 9:13am
